An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset Seizures

NCT01607346 · clinicaltrials.gov ↗

PHASE4

Phase

TERMINATED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Epilepsy

Interventions

DRUG: ezogabine/retigabine

Sponsor

GlaxoSmithKline